Therapeutic targeting of autophagy in myocardial infarction and heart failure

Jaime A Riquelme1, Myra N Chavez1,2, David Mondaca-Ruff1

  • 1a Advanced Center for Chronic Disease (ACCDiS) & Center for Molecular Studies of the Cell (CEMC), Facultad de Ciencias Químicas y Farmacéuticas & Facultad de Medicina , Universidad de Chile , Santiago , Chile.

Insights

Targeting autophagy, a cellular process, shows promise for treating myocardial infarction (MI) and heart failure (HF). Myocardial-specific strategies are needed to avoid systemic side effects in clinical trials.

Area of Science:

  • Cardiovascular Medicine
  • Cellular Biology
  • Molecular Medicine

Background:

  • Myocardial infarction (MI) is a primary cause of mortality.
  • Heart failure (HF) frequently follows non-lethal MI, presenting a significant clinical challenge.
  • Autophagy modulation is an emerging therapeutic strategy for MI and HF.

Purpose of the Study:

  • To review the current understanding of autophagy's role in MI and HF.
  • To explore pharmacological and genetic approaches for modulating autophagy.
  • To discuss the potential of autophagy targeting in myocardial regeneration.

Main Methods:

  • Comprehensive PubMed literature search.
  • Review of existing research on autophagy in cardiovascular diseases.
  • Analysis of therapeutic strategies for autophagy modulation.

Main Results:

  • Autophagy plays a critical role in the pathophysiology of MI and HF.
  • Pharmacological and genetic interventions can modulate autophagy.
  • Targeting autophagy may aid in myocardial regeneration.

Conclusions:

  • Autophagy modulation holds significant therapeutic potential for MI and HF.
  • Development of myocardium-specific autophagy targeting strategies is crucial for clinical translation.
  • Further research is needed to optimize autophagy-based therapies for cardiovascular diseases.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
6.0K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.8K